SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Mahalia Jackson Synthetic CCD

PatientMahalia Jackson
Date of birth1973-10-26
IdentifiersMRN HR-ML035-SYN; SSN (made up) 000-35-4692
Document date2026-11-01
AuthorBeatrice Fontenot, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood tests. Concerns: Short of breath on stairs and on stage for about three months, with a dry cough, tiredness and tightness in the chest; she runs out of breath in the middle of long phrases; twice her heart has raced and she felt faint while singing; She was told after an operation twelve years ago that she had sarcoidosis; no record of that operation is available to this clinic, and she wants a clear answer and a plan that a working singer can keep; Her spring concerts and recording sessions are booked; she does not want to cancel unless she has to, and she needs her voice. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning40 mg each morningOral route2026-03-09 to 2026-05-11completedS
Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks30 mg each morning for four weeksOral route2026-05-11 to 2026-06-08completedS
Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks20 mg each morning for four weeksOral route2026-06-08 to 2026-07-06completedS
Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks15 mg each morning for four weeksOral route2026-07-06 to 2026-08-03completedS
Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning10 mg each morningOral route2026-08-03 to 2026-09-21completedS
Prednisone 5 mg oral tablet, one and a half tablets (7.5 mg) by mouth each morning7.5 mg each morningOral route2026-09-21activeS
Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays15 mg once weeklyOral route2026-03-09 to 2026-05-11completedS
Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays20 mg once weeklyOral route2026-05-11activeS
Folic acid 1 mg oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-03-09activeS
Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food1500 mg once daily with foodOral route2026-03-09 to 2026-07-06completedS
Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutesOne tablet once weeklyOral route2026-03-16activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-03-09activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-05-11activeS

Procedures

ProcedureDatesStatusEvidence
Chest radiograph, two views: bilateral symmetric hilar lymph node enlargement with right paratracheal widening and fine reticulonodular opacities in both upper zones; heart size normal; no effusion2026-02-09 to 2026-02-09completedS
Resting 12-lead ECG: sinus rhythm 84 per minute, PR interval 240 ms (first-degree atrioventricular block), QRS 100 ms, frequent unifocal ventricular ectopic beats; no Q waves; no previous ECG for comparison2026-02-09 to 2026-02-09completedS
High-resolution CT of the chest: symmetric hilar, subcarinal and right paratracheal lymph nodes up to 2.4 cm, some with fine calcification; perilymphatic micronodules along the bronchovascular bundles and fissures in both upper lobes; no fibrosis, traction bronchiectasis or mass2026-02-11 to 2026-02-11completedS
Endobronchial ultrasound-guided transbronchial needle aspiration of lymph node stations 4R, 7 and 11L under moderate sedation, with bronchoalveolar lavage: non-necrotizing granulomas at all three stations; acid-fast and fungal stains negative; mycobacterial and fungal cultures sent; lavage lymphocytes 32 percent with a CD4 to CD8 ratio of 5.2; no malignant cells2026-02-18 to 2026-02-18completedS
Advance care planning conversation, about 30 minutes, including her wishes about the defibrillator2026-10-05 to 2026-10-05completedS
Full pulmonary function tests (spirometry, lung volumes and diffusing capacity): FVC 74 percent, FEV1 76 percent of predicted, FEV1/FVC 80 percent, total lung capacity 78 percent, DLCO 62 percent of predicted: mild restriction with a reduced diffusing capacity2026-02-23 to 2026-02-23completedS
24-hour Holter monitoring: sinus rhythm 58 to 112 per minute; PR interval 230 to 250 ms throughout; ventricular ectopic beats 6 percent of all beats, unifocal; three runs of nonsustained ventricular tachycardia of up to 8 beats; no second- or third-degree atrioventricular block; palpitations recorded during a run of ectopic beats2026-02-24 to 2026-02-24completedS
Transthoracic echocardiogram: left ventricular ejection fraction 47 percent with thinning and hypokinesis of the basal anteroseptum; normal right ventricle; normal valves; estimated pulmonary artery systolic pressure 28 mmHg; no pericardial effusion2026-02-26 to 2026-02-26completedS
Cardiac MRI with late gadolinium enhancement: left ventricular ejection fraction 47 percent; patchy mid-wall and subepicardial enhancement of the basal anteroseptum and inferolateral wall (about 9 percent of left ventricular mass), with raised T2 signal in the basal septum; right ventricle normal2026-03-03 to 2026-03-03completedS
Dilated eye examination by ophthalmology: no anterior or posterior uveitis, no conjunctival nodules, intraocular pressure 15 and 16 mmHg, no cataract2026-03-04 to 2026-03-04completedS
Cardiac FDG-PET with perfusion imaging, after 72 hours of a high-fat, very-low-carbohydrate diet and an overnight fast: focal FDG uptake in the basal anteroseptum and lateral wall (maximum SUV 6.2) matching the MRI enhancement, with a mild perfusion defect at the same sites; FDG-avid hilar and mediastinal lymph nodes; no uptake elsewhere outside the chest2026-03-06 to 2026-03-06completedS
Bone density scan (DXA): lumbar spine T-score -1.2, femoral neck T-score -1.6; FRAX adjusted for prednisone of 7.5 mg or more: major osteoporotic fracture 9 percent and hip fracture 1.2 percent at ten years (moderate risk)2026-03-16 to 2026-03-16completedS
Electrophysiology study: HV interval 58 ms; sustained monomorphic ventricular tachycardia (220 per minute) induced with double extrastimuli from the right ventricular apex, ended by overdrive pacing2026-03-18 to 2026-03-18completedS
Implantation of a dual-chamber transvenous cardioverter-defibrillator through the left subclavian vein, programmed with ventricular tachycardia therapies and minimal ventricular pacing; enrolled in remote monitoring; no complications2026-03-19 to 2026-03-19completedS
Repeat spirometry and diffusing capacity after nine weeks of treatment: FVC 84 percent and FEV1 85 percent of predicted, FEV1/FVC 80 percent, DLCO 70 percent of predicted2026-05-11 to 2026-05-11completedS
Repeat cardiac FDG-PET with the same preparation after five months of treatment: no myocardial FDG uptake; perfusion normal; hilar and mediastinal nodes smaller with low uptake2026-08-17 to 2026-08-17completedS
Repeat transthoracic echocardiogram: left ventricular ejection fraction 54 percent; basal septal thinning unchanged; normal right ventricle2026-08-17 to 2026-08-17completedS
Repeat spirometry and diffusing capacity after six months of treatment: FVC 90 percent and FEV1 89 percent of predicted, FEV1/FVC 79 percent, DLCO 76 percent of predicted2026-08-24 to 2026-08-24completedS

Immunizations

DateVaccineStatusEvidence
2020-11-16Tdap vaccinecompletedS
2026-02-09Influenza vaccine, this season (inactivated), late in the seasoncompletedS
2026-03-09Pneumococcal conjugate vaccine (PCV20), before immunosuppressioncompletedS
2026-03-09Recombinant zoster vaccine, dose 1 of 2completedS
2026-03-09Hepatitis B vaccine (adjuvanted, two-dose series), dose 1completedS
2026-05-11Hepatitis B vaccine (adjuvanted, two-dose series), dose 2completedS
2026-08-24Recombinant zoster vaccine, dose 2 of 2completedS
2026-10-05Influenza vaccine, this season (inactivated)completedS
2026-10-05COVID-19 mRNA vaccine, this season's formulacompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1952Breathlessness and abdominal cramping during a concert tour abroad at 40, with weight loss and a cancelled tour; hysterectomy afterwards, at which granulomas were reported in the abdomen and sarcoidosis was diagnosed; no pathology report availableD (CLM-0005)

Family History

RelativeConditionAge at deathEvidence
motherDied when she was six; cause not recorded in the cited sourceD (CLM-0001)

Health Concerns

ConcernStatusEvidence
Short of breath on stairs and on stage for about three months, with a dry cough, tiredness and tightness in the chest; she runs out of breath in the middle of long phrases; twice her heart has raced and she felt faint while singingactiveS
She was told after an operation twelve years ago that she had sarcoidosis; no record of that operation is available to this clinic, and she wants a clear answer and a plan that a working singer can keepactiveS
Her spring concerts and recording sessions are booked; she does not want to cancel unless she has to, and she needs her voiceactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13 on 2026-08-24; Leukocytes [#/volume] in Blood by Automated count 8.1 on 2026-08-24; Lymphocytes [#/volume] in Blood by Automated count 1.4 on 2026-08-24; Platelets [#/volume] in Blood by Automated count 248 on 2026-08-24; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-05-11; Potassium [Moles/volume] in Serum or Plasma 3.9 on 2026-05-11; Creatinine [Mass/volume] in Serum or Plasma 0.9 on 2026-08-24; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 77 on 2026-08-24; Glucose [Mass/volume] in Serum or Plasma 108 on 2026-08-24; Calcium [Mass/volume] in Serum or Plasma 9.5 on 2026-08-24; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 29 on 2026-08-24; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-08-24; Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma 90 on 2026-08-24; Albumin [Mass/volume] in Serum or Plasma 4.1 on 2026-08-24; Hemoglobin A1c/Hemoglobin.total in Blood 6.2 on 2026-08-24; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 34 on 2026-08-24; 1,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma 84 on 2026-02-09; Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 96 on 2026-08-24; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-02-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-02-09; FVC measured/predicted 90 on 2026-08-24; FEV1 measured/predicted 89 on 2026-08-24; FEV1/FVC 79 on 2026-08-24; Diffusion capacity.carbon monoxide/Predicted 76 on 2026-08-24; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-10-05; Cholesterol [Mass/volume] in Serum or Plasma 204 on 2026-10-05; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-10-05; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 126 on 2026-10-05; Triglyceride [Mass/volume] in Serum or Plasma 118 on 2026-10-05 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excludedresolvedconfirmed R06.09S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation.
Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked forresolvedconfirmed R00.2S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed.
Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raisedresolvedconfirmed E83.52S — Synthetic finding; resolved on treatment.
Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosisactiveconfirmed D86.2S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable).
Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolvedresolvedconfirmed J04.0S — Synthetic acute infection; not a historical claim.
Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heartactiveconfirmed D86.85S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R.
Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manageactiveconfirmed Z79.52S — Synthetic treatment status.
Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoringactiveconfirmed Z95.810S — Synthetic device status after the synthetic implant.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-09Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
2026-02-09Leukocytes [#/volume] in Blood by Automated count4.610*3/uL4-11 10*3/uLNormalS
2026-02-09Lymphocytes [#/volume] in Blood by Automated count0.910*3/uL1-4.8 10*3/uLLowS
2026-02-09Platelets [#/volume] in Blood by Automated count23210*3/uL150-400 10*3/uLNormalS
2026-02-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-02-09Potassium [Moles/volume] in Serum or Plasma4.1mmol/L3.5-5.1 mmol/LNormalS
2026-02-09Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.59-1.04 mg/dLHighS
2026-02-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M62mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-09Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
2026-02-09Calcium [Mass/volume] in Serum or Plasma10.8mg/dL8.6-10.3 mg/dLHighS
2026-02-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-35 U/LNormalS
2026-02-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L8-35 U/LNormalS
2026-02-09Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma128U/L35-104 U/LHighS
2026-02-09Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-02-09Hemoglobin A1c/Hemoglobin.total in Blood5.9%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-02-0925-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma22ng/mL30-100 ng/mLLowS
2026-02-091,25-Dihydroxyvitamin D [Mass/volume] in Serum or Plasma84pg/mL18-72 pg/mLHighS
2026-02-09Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma210pg/mL<=125 pg/mLHighS
2026-02-09Thyrotropin [Units/volume] in Serum or Plasma1.8m[IU]/L0.4-4.5 mIU/LNormalS
2026-02-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-02-23FVC measured/predicted74%>=80%LowS
2026-02-23FEV1 measured/predicted76%>=80%LowS
2026-02-23FEV1/FVC80%>=70%NormalS
2026-02-23Diffusion capacity.carbon monoxide/Predicted62%>=80%LowS
2026-02-23Calcium [Mass/volume] in Serum or Plasma10.7mg/dL8.6-10.3 mg/dLHighS
2026-02-23Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.59-1.04 mg/dLNormalS
2026-02-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M65mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
2026-03-09Hemoglobin [Mass/volume] in Blood12.6g/dL12-15.5 g/dLNormalS
2026-03-09Leukocytes [#/volume] in Blood by Automated count4.810*3/uL4-11 10*3/uLNormalS
2026-03-09Lymphocytes [#/volume] in Blood by Automated count0.910*3/uL1-4.8 10*3/uLLowS
2026-03-09Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
2026-03-09Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.59-1.04 mg/dLNormalS
2026-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M66mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-09Glucose [Mass/volume] in Serum or Plasma101mg/dL70-99 mg/dLHighS
2026-03-09Calcium [Mass/volume] in Serum or Plasma10.6mg/dL8.6-10.3 mg/dLHighS
2026-03-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-35 U/LNormalS
2026-03-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L8-35 U/LNormalS
2026-03-09Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma124U/L35-104 U/LHighS
2026-03-09Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2026-03-09Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma240pg/mL<=125 pg/mLHighS
2026-03-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
2026-05-11Hemoglobin [Mass/volume] in Blood13.1g/dL12-15.5 g/dLNormalS
2026-05-11Leukocytes [#/volume] in Blood by Automated count9.810*3/uL4-11 10*3/uLNormalS
2026-05-11Lymphocytes [#/volume] in Blood by Automated count1.210*3/uL1-4.8 10*3/uLNormalS
2026-05-11Platelets [#/volume] in Blood by Automated count26210*3/uL150-400 10*3/uLNormalS
2026-05-11Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-05-11Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
2026-05-11Creatinine [Mass/volume] in Serum or Plasma0.92mg/dL0.59-1.04 mg/dLNormalS
2026-05-11Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M75mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-05-11Glucose [Mass/volume] in Serum or Plasma118mg/dL70-99 mg/dLHighS
2026-05-11Calcium [Mass/volume] in Serum or Plasma9.6mg/dL8.6-10.3 mg/dLNormalS
2026-05-11Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS
2026-05-11Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L8-35 U/LNormalS
2026-05-11Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma96U/L35-104 U/LNormalS
2026-05-11Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-05-11Hemoglobin A1c/Hemoglobin.total in Blood6.3%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-05-1125-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mL30-100 ng/mLLowS
2026-05-11Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma140pg/mL<=125 pg/mLHighS
2026-05-11FVC measured/predicted84%>=80%NormalS
2026-05-11FEV1 measured/predicted85%>=80%NormalS
2026-05-11FEV1/FVC80%>=70%NormalS
2026-05-11Diffusion capacity.carbon monoxide/Predicted70%>=80%LowS
2026-05-11Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
2026-08-24Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
2026-08-24Leukocytes [#/volume] in Blood by Automated count8.110*3/uL4-11 10*3/uLNormalS
2026-08-24Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
2026-08-24Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-08-24Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.59-1.04 mg/dLNormalS
2026-08-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M77mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-24Glucose [Mass/volume] in Serum or Plasma108mg/dL70-99 mg/dLHighS
2026-08-24Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-08-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L7-35 U/LNormalS
2026-08-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
2026-08-24Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma90U/L35-104 U/LNormalS
2026-08-24Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-08-24Hemoglobin A1c/Hemoglobin.total in Blood6.2%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-08-2425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2026-08-24Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma96pg/mL<=125 pg/mLNormalS
2026-08-24FVC measured/predicted90%>=80%NormalS
2026-08-24FEV1 measured/predicted89%>=80%NormalS
2026-08-24FEV1/FVC79%>=70%NormalS
2026-08-24Diffusion capacity.carbon monoxide/Predicted76%>=80%LowS
2026-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
2026-10-05Cholesterol [Mass/volume] in Serum or Plasma204mg/dL<=200 mg/dLHighS
2026-10-05Cholesterol in HDL [Mass/volume] in Serum or Plasma54mg/dL>=50 mg/dLNormalS
2026-10-05Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation126mg/dL<=129 mg/dLNormalS
2026-10-05Triglyceride [Mass/volume] in Serum or Plasma118mg/dL<=149 mg/dLNormalS
2026-10-05Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-09Body height170cmS
2026-02-09Body weight92kgS
2026-02-09Body mass index (BMI) [Ratio]31.8kg/m2S
2026-02-09Systolic blood pressure128mm[Hg]S
2026-02-09Diastolic blood pressure80mm[Hg]S
2026-02-09Heart rate86/minS
2026-02-09Respiratory rate18/minS
2026-02-09Body temperature36.8CelS
2026-02-09Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-02-23Body height170cmS
2026-02-23Body weight91.6kgS
2026-02-23Body mass index (BMI) [Ratio]31.7kg/m2S
2026-02-23Systolic blood pressure126mm[Hg]S
2026-02-23Diastolic blood pressure78mm[Hg]S
2026-02-23Heart rate82/minS
2026-02-23Respiratory rate18/minS
2026-02-23Body temperature36.7CelS
2026-02-23Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-03-09Body height170cmS
2026-03-09Body weight91.2kgS
2026-03-09Body mass index (BMI) [Ratio]31.6kg/m2S
2026-03-09Systolic blood pressure124mm[Hg]S
2026-03-09Diastolic blood pressure78mm[Hg]S
2026-03-09Heart rate80/minS
2026-03-09Respiratory rate18/minS
2026-03-09Body temperature36.6CelS
2026-03-09Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-05-11Body height170cmS
2026-05-11Body weight94kgS
2026-05-11Body mass index (BMI) [Ratio]32.5kg/m2S
2026-05-11Systolic blood pressure138mm[Hg]S
2026-05-11Diastolic blood pressure86mm[Hg]S
2026-05-11Heart rate66/minS
2026-05-11Respiratory rate16/minS
2026-05-11Body temperature36.6CelS
2026-05-11Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-08-24Body height170cmS
2026-08-24Body weight93kgS
2026-08-24Body mass index (BMI) [Ratio]32.2kg/m2S
2026-08-24Systolic blood pressure130mm[Hg]S
2026-08-24Diastolic blood pressure82mm[Hg]S
2026-08-24Heart rate64/minS
2026-08-24Respiratory rate16/minS
2026-08-24Body temperature36.7CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S
2026-06-15Body height170cmS
2026-06-15Body weight93.4kgS
2026-06-15Body mass index (BMI) [Ratio]32.3kg/m2S
2026-06-15Systolic blood pressure134mm[Hg]S
2026-06-15Diastolic blood pressure84mm[Hg]S
2026-06-15Heart rate72/minS
2026-06-15Respiratory rate16/minS
2026-06-15Body temperature37.4CelS
2026-06-15Oxygen saturation in Arterial blood by Pulse oximetry97%S
2026-10-05Body height170cmS
2026-10-05Body weight92.2kgS
2026-10-05Body mass index (BMI) [Ratio]31.9kg/m2S
2026-10-05Systolic blood pressure128mm[Hg]S
2026-10-05Diastolic blood pressure80mm[Hg]S
2026-10-05Heart rate66/minS
2026-10-05Respiratory rate16/minS
2026-10-05Body temperature36.7CelS
2026-10-05Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
2026-02-09Three months of breathlessness, cough, tiredness and palpitations in a touring singer of 52: examination, chest radiograph, ECG and blood testsfinishedS
2026-02-23EBUS result: sarcoidosis; pulmonology consultation, lung function, screening for other organ involvement, and cardiac testsfinishedS
2026-03-09Cardiac MRI and FDG-PET results: cardiac sarcoidosis; start of prednisone and methotrexate, bone and infection protection, and electrophysiology referralfinishedS
2026-05-11Nine weeks of treatment: lung function, calcium, methotrexate safety, the new defibrillator, steroid effects, and her concert schedulefinishedS
2026-08-24Six months of treatment: repeat FDG-PET, steroid taper, and plans for touringfinishedS
2026-06-15Same-day sick visit for laryngitis on immunosuppressive treatmentfinishedS
2026-10-05Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Pulmonology (sarcoidosis) consultation within two weeks, with EBUS-guided lymph node sampling arranged directly from the referral, to confirm the diagnosis and plan treatmentcompletedGL-ATS-SARC-2020, GL-ERS-SARC-2021S
Diagnosis of suspected sarcoidosis: chest radiograph and CT of the chest, tissue by EBUS-guided needle aspiration rather than mediastinoscopy, stains and cultures for mycobacteria and fungi, an interferon-gamma release assay and HIV test to exclude other causes; serum ACE is not used to make or exclude the diagnosiscompletedGL-ATS-SARC-2020S
Screening every patient with suspected sarcoidosis for other organ involvement: ECG, serum calcium with 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, creatinine, liver tests and alkaline phosphatase, complete blood count, TSH, and an eye examination; stop the calcium and vitamin D supplement while calcium is highcompletedGL-ATS-SARC-2020S
Cardiac evaluation for suspected cardiac sarcoidosis (abnormal ECG and palpitations): 24-hour Holter monitoring, echocardiogram, cardiac MRI with late gadolinium enhancement, and cardiac FDG-PET with a dietary preparation, all before glucocorticoids begin; cardiology and electrophysiology reviewcompletedGL-HRS-CS-2014, GL-AHA-CS-2024, GL-ATS-SARC-2020S
Treatment of cardiac and pulmonary sarcoidosis: prednisone 40 mg daily, tapered over about six months toward 5 to 10 mg, with methotrexate 15 mg weekly (increased to 20 mg) and folic acid, continued for at least a year for cardiac disease; repeat FDG-PET after about six monthscompletedGL-ERS-SARC-2021, GL-AHA-CS-2024, GL-HRS-CS-2014S
Methotrexate safety: hepatitis B and C screening before starting, blood count, liver tests and creatinine every two to four weeks for the first three months and then every eight to twelve weeks, no alcohol, and no trimethoprim-sulfamethoxazole while on methotrexatecompletedGL-ACR-DMARD-2012, GL-ERS-SARC-2021S
Glucocorticoid protection: bone density scan and FRAX, alendronate weekly, dietary calcium only (no supplements while calcium was high), vitamin D replaced cautiously once calcium is normal, with calcium rechecked; atovaquone pneumocystis prophylaxis while prednisone is 20 mg or more with methotrexate; glucose, blood pressure, weight, mood, sleep and eye pressure checkscompletedGL-ACR-GIOP-2022, GL-CMID-2026, GL-ERS-SARC-2021S
Vaccination before immunosuppression: PCV20, recombinant zoster vaccine, hepatitis B vaccine for a non-immune adult, influenza and COVID-19 vaccines; no live vaccines while on prednisone and methotrexatecompletedGL-CDC-IMZ-2026S
Arrhythmia risk: metoprolol for ventricular ectopy; electrophysiology study for a left ventricular ejection fraction above 35 percent with scar on MRI and nonsustained ventricular tachycardia, and a dual-chamber defibrillator if sustained ventricular tachycardia is induced; remote device monitoring, including on tourcompletedGL-HRS-CS-2014, GL-AHA-CS-2024S
Performing and travel: concerts paused until the defibrillator wound has healed and the first device check is done, then a lighter schedule with rest days, voice care, and a travel letter with her device card and medicine list; no driving for one week after the implantcompletedGL-HRS-CS-2014, GL-ERS-SARC-2021S
Depression screening at each phase, plain explanations with written information, and support she chooses; she decides who receives each notecompletedGL-USPSTF-DEP-2023S

Goals

GoalTargetStatusOutcomeProvenance
Tissue diagnosis with other causes excluded, and screening of the eyes, heart, calcium, liver and kidneys, within four weeks of presentation2026-03-09completedEBUS in nine days; eye examination, Holter, echocardiogram, cardiac MRI and FDG-PET within four weeksS
Calcium in the normal range within three months2026-05-11completedCalcium 9.6 mg/dL after nine weeks of treatmentS
FVC and DLCO improved by at least 10 percent of predicted within six months2026-08-24completedFVC 74 to 90 percent and DLCO 62 to 76 percent of predictedS
No myocardial FDG uptake on repeat PET after about six months of treatment, with left ventricular function stable or better2026-08-24completedMyocardial uptake resolved; ejection fraction 54 percent from 47S
Prednisone at 10 mg a day or less by six months, with methotrexate as the steroid-sparing agent2026-08-24completedPrednisone 10 mg at six months and taperingS
Back on stage with a schedule she can sustain, with her voice protected2026-08-24completedTwo concerts a week since late spring; a longer autumn tour plannedS

Functional Status

Mental Status